Biomarkers for primary biliary cholangitis: current perspectives

Elias Kouroumalis,1 Demetrius Samonakis,2 Argyro Voumvouraki3 1Department of Gastroenterology, University Hospital and Medical School, University of Crete, Heraklion, Crete, Greece; 2Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece; 3Department of Medicine, AHEPA Unive...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kouroumalis E, Samonakis D, Voumvouraki A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Primary Biliary Cholangitis Autoantibodies microRNAs proteomics treatment response Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/86527673b59f4b8592547486d959c5cd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86527673b59f4b8592547486d959c5cd
record_format	dspace
spelling	oai:doaj.org-article:86527673b59f4b8592547486d959c5cd2021-12-02T08:48:10ZBiomarkers for primary biliary cholangitis: current perspectives1179-1535https://doaj.org/article/86527673b59f4b8592547486d959c5cd2018-06-01T00:00:00Zhttps://www.dovepress.com/biomarkers-for-primary-biliary-cholangitis-current-perspectives-peer-reviewed-article-HMERhttps://doaj.org/toc/1179-1535Elias Kouroumalis,1 Demetrius Samonakis,2 Argyro Voumvouraki3 1Department of Gastroenterology, University Hospital and Medical School, University of Crete, Heraklion, Crete, Greece; 2Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece; 3Department of Medicine, AHEPA University Hospital, Thessaloniki, Greece Abstract: Primary biliary cholangitis (PBC) is a chronic progressive cholestatic disease characterized by destruction of small- and medium-sized intrahepatic bile ducts. It is no longer a rare disease, since many new asymptomatic cases are incidentally identified. Liver biopsy is diagnostically critical but not always feasible or practical to be performed. Many potential, noninvasive, markers have been proposed to replace liver biopsy and further provide the assessment of disease severity and ultimate prognosis. In this review, we evaluated serum biomarkers proposed for diagnosis, extent of fibrosis, disease prognosis and attempts for early prediction of treatment response. Older biochemical and immunological markers are presented along with recent reports including the role of microRNAs and promising results based on proteomics and metabolomics. Keywords: primary biliary cholangitis, autoantibodies, microRNAs, proteomics, treatment responseKouroumalis ESamonakis DVoumvouraki ADove Medical PressarticlePrimary Biliary CholangitisAutoantibodiesmicroRNAsproteomicstreatment responseDiseases of the digestive system. GastroenterologyRC799-869ENHepatic Medicine: Evidence and Research, Vol Volume 10, Pp 43-53 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Primary Biliary Cholangitis Autoantibodies microRNAs proteomics treatment response Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	Primary Biliary Cholangitis Autoantibodies microRNAs proteomics treatment response Diseases of the digestive system. Gastroenterology RC799-869 Kouroumalis E Samonakis D Voumvouraki A Biomarkers for primary biliary cholangitis: current perspectives
description	Elias Kouroumalis,1 Demetrius Samonakis,2 Argyro Voumvouraki3 1Department of Gastroenterology, University Hospital and Medical School, University of Crete, Heraklion, Crete, Greece; 2Department of Gastroenterology, University Hospital of Heraklion, Crete, Greece; 3Department of Medicine, AHEPA University Hospital, Thessaloniki, Greece Abstract: Primary biliary cholangitis (PBC) is a chronic progressive cholestatic disease characterized by destruction of small- and medium-sized intrahepatic bile ducts. It is no longer a rare disease, since many new asymptomatic cases are incidentally identified. Liver biopsy is diagnostically critical but not always feasible or practical to be performed. Many potential, noninvasive, markers have been proposed to replace liver biopsy and further provide the assessment of disease severity and ultimate prognosis. In this review, we evaluated serum biomarkers proposed for diagnosis, extent of fibrosis, disease prognosis and attempts for early prediction of treatment response. Older biochemical and immunological markers are presented along with recent reports including the role of microRNAs and promising results based on proteomics and metabolomics. Keywords: primary biliary cholangitis, autoantibodies, microRNAs, proteomics, treatment response
format	article
author	Kouroumalis E Samonakis D Voumvouraki A
author_facet	Kouroumalis E Samonakis D Voumvouraki A
author_sort	Kouroumalis E
title	Biomarkers for primary biliary cholangitis: current perspectives
title_short	Biomarkers for primary biliary cholangitis: current perspectives
title_full	Biomarkers for primary biliary cholangitis: current perspectives
title_fullStr	Biomarkers for primary biliary cholangitis: current perspectives
title_full_unstemmed	Biomarkers for primary biliary cholangitis: current perspectives
title_sort	biomarkers for primary biliary cholangitis: current perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/86527673b59f4b8592547486d959c5cd
work_keys_str_mv	AT kouroumalise biomarkersforprimarybiliarycholangitiscurrentperspectives AT samonakisd biomarkersforprimarybiliarycholangitiscurrentperspectives AT voumvourakia biomarkersforprimarybiliarycholangitiscurrentperspectives
_version_	1718398374071238656

Biomarkers for primary biliary cholangitis: current perspectives

Ejemplares similares